Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran
loading…
Catalogue record: Dublin Core XML — 10665-385346.dc.xml the item's metadata record · KG node — item-10665-385346.json the item's catalogue node, on GitHub · hdl:10665/385346 the item upstream
Summary
Background: Pneumococcal disease caused by Streptococcus pneumoniae results in considerable mortality and morbidity. Pneumococcal conjugate vaccines (PCV), such as PCV-13, can prevent invasive pneumococcal disease and avoid disability and death. The cost of introducing PCV-13 in childhood immunization schedules should be assessed against the cost of pneumococcal diseases for each community. Aims: This study aimed to evaluate the cost–effectiveness of introducing PCV-13 in the national immunization programme for children under 5 years in the Islamic Republic of Iran. Methods: The TRIVAC decision support model was used to estimate total costs of introducing PCV-13 and the disability-adjusted life years (DALYs)averted. The main pneumococcal diseases were considered—pneumonia, meningitis, acute otitis media, and non-pneumonia, non-meningitis infections—in terms of hospital admissions, outpatient visits and deaths. Local data were used to estimate costs. Results: Pneumococcal disease is estimated to affect 18 713 211 children under 5 years (519 412 pneumonia, 18 148 116 acute otitis media, 6884 meningitis, and 38 799 non-pneumonia, non-meningitis)in 10 years (2014–2023)without use of the vaccine. Introduction of PCV-13 would prevent 4 900 084 cases of pneumococcal disease (190 849 pneumonia, 4 692 450 acute otitis media, 2529 meningitis, and 14 256 non-pneumonia, non-meningitis). Pneumococcal infection would cause 287 950 hospital admissions and 29 399 deaths; vaccination could avert 105 802 hospital admissions and 9997 deaths. The incremental cost–effectiveness was estimated to be US$ 1890 and US$ 1538 per averted DALY for the government and society respectively. Conclusion: According to WHO-recommended thresholds for interpreting cost–effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective
The abstract from the item's catalogue record, as WHO published it.
10665-385346.pdf is not held on this site. Find it at 10203397-2019-2510-686-697.pdf at its source.
The whole library
Source JSON-LD and assets
The published files this page is a rendering of.
- manifest.jsonld the entry's JSON-LD
- structure.json ingestion structure (JSON), on GitHub
- sections/ section nodes (JSON-LD) and their text, on GitHub
- blocks/ block nodes (JSON-LD), on GitHub
- 10665-385346.doc.json document projection (JSON)
- 10665-385346.json block projection (JSON)
- 10665-385346.png avatar (cover)